Connor, Clark & Lunn Investment Management (CC&L)
MCRB icon

Connor, Clark & Lunn Investment Management (CC&L)’s Seres Therapeutics MCRB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,504
Closed -$450K – 1346
2022
Q3 		$450K Buy
3,504
+854
+32% +$87.5K ﹤0.01% 833
2022
Q2 		$182K Sell
2,650
-6,154
-70% -$530K ﹤0.01% 943
2022
Q1 		$1.25M Sell
8,804
-2,094
-19% -$322K 0.01% 617
2021
Q4 		$1.82M Buy
10,898
+8,499
+354% +$1.35M 0.01% 553
2021
Q3 		$334K Buy
2,399
+816
+52% +$160K ﹤0.01% 849
2021
Q2 		$755K Buy
+1,583
New +$668K ﹤0.01% 711
2019
Q2 		– Sell
-855
Closed -$117K – 1044
2019
Q1 		$117K Buy
855
+30
+4% +$3.66K ﹤0.01% 858
2018
Q4 		$75K Buy
825
+25
+3% +$3.5K ﹤0.01% 913
2018
Q3 		$121K Buy
800
+120
+18% +$19.4K ﹤0.01% 880
2018
Q2 		$117K Buy
+680
New +$111K ﹤0.01% 988
2017
Q2 		– Sell
-1,893
Closed -$427K – 885
2017
Q1 		$427K Buy
1,893
+1,139
+151% +$231K ﹤0.01% 654
2016
Q4 		$149K Buy
+754
New +$164K ﹤0.01% 816

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MCRB Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 3,504 shares — an estimated $450K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MCRB in Q4 2016 and held it in 12 quarters. The position peaked at $1.82M in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 3,504 Seres Therapeutics shares in Q4 2022, an estimated $450K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Seres Therapeutics in Q4 2016 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Seres Therapeutics position peaked at $1.82M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.